It has now been two years since new final, regulations from SAMHSA and the DEA regarding buprenorphine and methadone provided greater flexibilities for the treatment of Opioid Use Disorder (OUD). The Coalition of Medication-Assisted Treatment Providers and Advocates (COMPA) is hosting a full-day symposium to examine the impact of those changes—the first set of comprehensive...Continue Reading